Corcept Appoints Monica Tellado as President, Emerging Markets
01 Novembre 2023 - 1:00PM
Corcept Therapeutics Incorporated (NASDAQ: CORT), a
commercial-stage company engaged in the discovery and development
of medications to treat severe endocrine, oncology, metabolism, and
neurology disorders by modulating the effects of the hormone
cortisol, today announced the appointment of Monica Tellado as
President, Emerging Markets. She will report to Joseph K. Belanoff,
MD, Corcept’s Chief Executive Officer, and join the company’s
Executive Team.
Ms. Tellado’s prior role was at Heartflow, where
she served as Chief Financial Officer. Before joining Heartflow,
Ms. Tellado spent 19 years in ascending leadership roles at Gilead
Sciences, including Senior Vice President of Finance and Investor
Relations; Vice President of Sales and Marketing for the company’s
Liver Disease Business Unit; and Vice President of Commercial
Operations, where she led efforts to launch products across HIV,
liver diseases, cardiopulmonary diseases, and oncology.
At Corcept, Ms. Tellado will serve as the global
commercial lead for therapeutics in metabolism and neurology. She
will also oversee pipeline and portfolio planning activities across
the company’s other therapeutic areas.
“We are thrilled to welcome Monica to Corcept,”
said Dr. Belanoff. “Her expertise in commercial planning and
product launches make her a valuable addition to our team as we
work to realize the full therapeutic potential of cortisol
modulation.”
The appointment of Ms. Tellado comes on the
heels of Corcept’s initiation of MONARCH, a Phase 2b trial of its
proprietary selective cortisol modulator miricorilant in patients
with non-alcoholic steatohepatitis (NASH). By the end of next year,
the company also anticipates results from its Phase 2 DAZALS study,
investigating dazucorilant in patients with amyotrophic lateral
sclerosis (ALS).
“Corcept is a truly innovative company with a
collaborative approach to unlocking the potential of cortisol
modulation. I’m delighted to join the organization at such an
exciting time in its evolution,” said Ms. Tellado.
About Corcept Therapeutics
For more than 25 years, Corcept’s focus on
cortisol modulation and its potential to treat patients across a
wide variety of serious disorders has led to the discovery of more
than 1,000 proprietary selective cortisol modulators. Corcept’s
advanced clinical trials are being conducted in patients with
hypercortisolism, solid tumors, amyotrophic lateral sclerosis (ALS)
and liver disease (NASH). In February 2012, the company introduced
Korlym®, the first medication approved by the U.S. Food and Drug
Administration for the treatment of patients with Cushing’s
syndrome. Corcept is headquartered in Menlo Park, California. For
more information, visit Corcept.com.
Forward-Looking Statements
Statements in this press release, other than
statements of historical fact, are forward-looking statements based
on our current plans and expectations that are subject to risks and
uncertainties that might cause our actual results to differ
materially from those such statements express or imply. These risks
and uncertainties include, but are not limited to, our ability to
operate our business; risks related to the development of
relacorilant, miricorilant, dazucorilant and our other product
candidates, including their clinical attributes, regulatory
approvals, mandates, oversight and other requirements; and the
scope and protective power of our intellectual property. These and
other risks are set forth in our SEC filings, which are available
at our website and the SEC’s website. We disclaim any intention or
duty to update forward-looking statements made in this press
release.
CONTACTInvestor
inquiries:ir@corcept.comMedia
inquiries:CorceptCommunications@corcept.com www.corcept.com
Grafico Azioni Corcept Therapeutics (NASDAQ:CORT)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Corcept Therapeutics (NASDAQ:CORT)
Storico
Da Set 2023 a Set 2024